Products will be available in up to 838 stores across the UK
Toronto, Ontario, Canada, Jan. 17, 2022 (GLOBE NEWSWIRE) — Yooma Wellness Inc. ("Yooma") (CSE: YOOM, AQSE: YOOM), a Toronto-based vertically-integrated global wellness platform that develops and markets a portfolio of CBD and wellness brands, is pleased to announce that Boots, one of the UK’s leading health and beauty retailers, will stock MYO Plant Nutrition ("MYO") products.
The listing includes MYO’s Plant Proteins in 838 stores, branched-chain amino acids (BCAA) and essential amino acids (EAA) in up to 574 stores, and functional sprays in 522 stores.
Launching with Boots accelerates the momentum MYO has already seen in 2021, with products now available in Holland & Barrett, Selfridges, Lloyds Pharmacy and Amazon, amongst others.
MYO products are 100%-plant-based, use clean and innovative ingredients, and focus on the growing area of full-body plant-based wellness, which includes nutrition, the gut, brain, immunity and other key elements of wellness. Furthermore, MYO holds a leading position with regards to sustainability by using recycled and recyclable outer packaging as well as biodegradable scoops and pouches.
James Lawson Baker, Founder of MYO Plant Nutrition, commented: “This is a major milestone for MYO and we are absolutely delighted to be partnering with Boots, the leading health and beauty retailer in the UK. A listing of this size gives the brand enormous national exposure and deepens our footprint within mainstream UK retail. The listing will support MYO in making plant-based active nutrition and wellness products mainstream and accessible. The partnership is a testament to the high-quality product and brand offering that we have built over the past year. We look forward to building our credibility amongst Boots’ customers going forward.”
Jordan Greenberg, CEO of Yooma, said: “MYO Plant Nutrition is an exceptional example of how Yooma’s buy-and-build strategy creates shareholder value. MYO continues to surpass expectations with its increased availability in some of UK’s most reputable retailers and it has the honour of being known as one of the few brands to have passed the FSA’s validation assessment.”
Yooma acquired MYO in March 2021 due to the growing market demand for plant-based protein supplements, with a global market size estimated at US$4.3 billion in 2020, projected to grow at a CAGR of 7.2% during a forecast period 2021-2026.1
About MYO Plant Nutrition
MYO Plant Nutrition is a UK-based plant nutrition business with a mission to help people improve their full-body wellness. With a comprehensive product portfolio, MYO helps address the key areas of wellness including nutrition, performance, immunity, cognitive health and gut health. MYO is one of the few brands whose CBD products have passed the UK Food Standard Agency’s (“FSA”) rigorous validation assessment and a number of products are included on the FSA’s public list. The brand is stocked in Boots, Holland & Barrett and Lloyds Pharmacy amongst others. For further information visit www.myoplantnutrition.com.
About Yooma Wellness Inc.
Yooma's mission is to build a vertically-integrated global leader in the manufacturing, marketing, distribution, and sale of wellness products including hemp seed oil and hemp-derived and cannabinoid (CBD) ingredients. The company leverages strategically curated sales channels and ecommerce networks to deliver a diverse mix of wellness products through operating subsidiaries in the United States, United Kingdom, France and Japan. Learn more at www.yooma.ca.
Media Contact:
Jordan Greenberg
Email: jgreenberg@yooma.ca
Phone: 1-512-823-1678
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to future financial or operating performance and other statements that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws and are based on current expectations, estimates and projections. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “will”, “growing”, “building”, “projected” or the negative of these words or other variations thereof, have been used to identify such forward-looking statements. Specific forward-looking statements include, without limitation, all disclosure regarding the rollout of MYO products in Boots stores, and the growing markets for plant-based protein supplements and full-body plant–based wellness products.
There are many risks and uncertainties that may affect forward-looking statements including, among others, regulatory risk in each jurisdiction in which Yooma and its subsidiaries do or intend to operate; the uncertainties, effects of and responses to the COVID-19 pandemic; reliance on licenses; competition; dependence on senior management and key personnel; general business risk and liability; regulation of the CBD industry; changes in laws, regulations and guidelines; compliance with laws; limited operating history; unfavourable publicity or consumer perception; product liability, risks related to intellectual property; product recalls; difficulties with forecasts; management of growth; litigation; changes in demand for CBD and wellness products; competition; changes in Yooma and its subsidiaries’ relationships with their commercial partners; and other risks. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, Yooma cannot be certain that actual results will be consistent with such forward-looking information. Yooma cautions you not to place undue reliance upon any such forward-looking statements. Yooma disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of Yooma.
1 https://www.industryarc.com/Research/Plant-Based-Protein-Supplements-Market-Research-508437?utm_source=ABnewswire&utm_medium=Pressrelease&utm_campaign=Paidpressrelease
(Bloomberg) — Just over a year ago, Margarita Louis-Dreyfus’s financial outlook looked grim. Most Read from BloombergDeadly Strikes on UAE Upset Efforts to Ease Gulf FrictionsOne of the World’s Wealthiest Oil Exporters Is Becoming UnlivableDjokovic Loses Shot at Tennis History as Australia Deports StarChina Cuts Interest Rate as Growth Risks Worsen With OmicronStocks, Futures Mixed as Bond Yields March Higher: Markets WrapThe Russian-born heiress was trying to sell a stake in Louis Dreyfus Co.,
Stop sinking your money in mediocre businesses. Buy the best instead.
In this article, we discuss the 10 dividend stocks to buy according to Ken Fisher based on Q3 holdings of his fund. If you want to skip our detailed analysis of Fisher’s history, investment philosophy, and hedge fund performance, go directly to the 5 Dividend Stocks to Buy According to Ken Fisher. Kenneth Lawrence Fisher […]
Tech stocks have been bruised. But this trio looks poised to pop in 2022.
Investors looking for a brief respite from two weeks of volatile trading on Wall Street may get one on Monday, when Martin Luther King Jr. Day is observed this year.
Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, no matter what direction the overall markets take, can sometimes be challenging. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is, to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the
Let’s not beat about the bush too much. At the end of the day every investor wants to see a strong return on their outlay. The stronger, the better. The thing is, the markets are predicated on a simple equation. Go with the safer bets, i.e. the mega-caps, and you will probably make bank, although less likely to see enormous gains. On the other hand, take a chance on a smaller, less established name and the rewards could be far grander. However, there’s a catch; this is a risky play and you are f
In this article, we discuss the 10 most popular tech stocks to consider on Reddit. If you want to skip our detailed analysis of these stocks, go directly to the Reddit Stock Portfolio: 5 Most Popular Tech Stocks To Consider. Reddit has become an important internet platform for the finance world in the past year […]
After touching the levels not seen since the Great Recession, AT&T Inc. (NYSE: T) is looking for a merger-propelled turnaround. While institutions are optimistic about the opportunities, the public rightfully remains uncertain about the future.
Tech stocks have gotten off to a rough start this year. For instance, the tech-heavy Nasdaq Composite index is down 5% so far. If this continues into full-blown correction territory, widely considered a 10% decline, investors can pick up certain tech stocks at good valuations.
In this article, we discuss 10 best dividend aristocrats to buy for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Dividend Aristocrats to Buy for 2022. In 2021, the S&P 500 dividend aristocrats included 65 companies from 11 diversified industries, exhibiting growth prospects and strong company […]
Many technology stocks took it on the nose in 2021. Cathie Wood's high-growth, tech stock-focused exchange traded fund (ETF) ARK Innovation (NYSEMKT: ARKK) took a hit last year and lost 24% of its value. The tech sector is stumbling out of the gate in 2022 as well, already down almost 10% versus an essentially flat index.
GlaxoSmithKline is courting the sovereign wealth funds of Qatar and Singapore as cornerstone investors in a listing of its £50bn consumer business as it seeks to head off a risky takeover by Unilever.
In this article, we discuss the 10 healthcare stocks to buy according to billionaire DE Shaw based on Q3 holdings of his fund. If you want to skip our detailed analysis of Shaw’s history, investment philosophy, and hedge fund performance, go directly to the 5 Healthcare Stocks to Buy According to Billionaire DE Shaw. David […]
Find out which of Vanguard's value funds are the best for building a solid core-satellite value investing strategy for your portfolio.
In this article, we discuss the 10 cryptocurrencies Reddit is buying for the next bull run. If you want to skip our detailed analysis of these currencies, go directly to the 5 Cryptocurrencies Reddit is Buying for the Next Bull Run. The past year was in many ways a defining one for the crypto industry. […]
As bitcoin heads into 2022, a growing cohort of long-term investors is doubling down on its stashes of the cryptocurrency, hoping a December dip was merely a festive blip. Since last July, for example, the amount of bitcoin held in digital wallets with no outflows for more than five months has been steadily increasing, according to digital currency brokerage Genesis Trading. "The number of bitcoins that haven't moved in over a year has been climbing since July," said Noelle Acheson, head of market insights at Genesis Trading.
Share prices of Rivian Automotive (NASDAQ: RIVN) briefly fell to $75.13 per share on Friday before closing the session at $79.95 per share. It was the first time Rivian stock dipped below its initial public offering (IPO) price of $78 per share. Howard Smith: Markets aren't always efficient, and that's how investors can gain an advantage.
The REITs are paying big dividends from diverse commercial property holdings.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a…
